Resumen
Introducción: la enfermedad de Pompe (EP) o glucogenosis tipo II es una enfermedad autosómica recesiva causada por mutaciones en el gen GAA que codifica para la proteína alfa-1,4-glucosidasa. Su deficiencia lleva a un almacenamiento anormal de glucógeno en los lisosomas de varias células, a través de los diferentes tejidos, lo que causa un compromiso musculoesquelético predominante.
Contenidos: los fenotipos de la enfermedad dependen de las variantes genéticas y de los niveles de la actividad enzimática residual. La enfermedad se presenta como EP de inicio infantil, EP de inicio tardío y EP intermedio, por lo que es de suma importancia su diagnóstico temprano, por medio de estudios moleculares como la secuenciación de Sanger y la secuenciación de nueva generación.
Conclusiones: se ha demostrado, mediante diferentes estudios, que las variaciones genéticas pueden diferir entre etnias, y es importante su caracterización molecular para determinar el tratamiento más adecuado, de acuerdo con el estado del material inmunológico de reacción cruzada (CRIM).
Citas
Simona T, Giuseppe C, Paolo C. Pompe disease: pathogenesis, molecular genetics and diagnosis. Aging 2020, Vol. 12, No. 15. https://doi.org/10.18632/aging.103794
Toscano A, Rodolico C, Musumeci O. Multisystem late onset pompe disease (LOPD): an update on clinical aspects. Ann Transl Med. 2019; 7:284. https://doi.org/10.21037/atm.2019.07.24
Musumeci O, la Marca G, Spada M, Mondello S, Danesino C, Comi GP, Pegoraro E, Antonini G, Marrosu G, Liguori R, Morandi L, Moggio M, Massa R, et al, and Italian GSD II group. LOPD study: looking for an early diagnosis in a late-onset pompe disease high-risk population. J Neurol Neurosurg Psychiatry. 2016; 87:5-11. https://doi.org/10.1136/jnnp-2014-310164
Musumeci O and Toscano A. Diagnostic tools in late onset Pompe disease (LOPD). Ann Transl Med 2019;7(13):286. https://doi.org/10.21037/atm.2019.06.60
Al-Lozi M, Amato A, Barohn R. Diagnostic criteria for late-onset (childhood and adult) pompe disease. Muscle nerve 40:149-160, 2009. https://doi.org/10.1002/mus.21393
Müller-Felber W, Horvath R, Gempel K, Podskarbi T, Shin Y, Pongratz D, Walter MC, Baethmann M, Schlotter-Weigel B, Lochmüller H, Schoser B. Late onset pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients. Neuromuscul Disord. 2007; 17:698-706. https://doi.org/10.1016/j.nmd.2007.06.002
Kassardjian CD, Engel AG, Sorenson EJ. Electromyographic findings in 37 patients with adult-onset acid maltase deficiency. Muscle Nerve 2015;51:759-61. https://doi.org/10.1002/mus.24620
Hirschhorn R, Reuser AJJ. Glycogen storage disease type II: acid a-glucosidase (acid maltase) deficiency. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, editors. The online metabolic and molecular bases of inherited disease, chap. 135. Scriver's OMMBID Website. http://www.ommbid.com/
Amato AA. Acid maltase deficiency and related myopathies. Neurol Clin 2000;18:151-165. https://doi.org/10.1016/S0733-8619(05)70182-1
Díaz-Manera J, Walter G, Volker Straub. Skeletal muscle magnetic resonance imaging in Pompe disease. Muscle & Nerve. 2020;1-11. https://doi.org/10.1002/mus.27099
Lollert A, Stihl C, Hötker AM, Mengel E, König J, Laudemann K, Gökce S, Düber C, Staatz G. Quantification of intramuscular fat in patients with late-onset pompe disease by conventional magnetic resonance imaging for the long-term follow-up of enzyme replacement therapy. PLoS One. 2018; 13:e0190784. https://doi.org/10.1371/journal.pone.0190784
Winchester B, Bali D, Bodamer OA, et al. Methods for a prompt and reliable laboratory diagnosis of Pompe disease: Report from an international consensus meeting. Mol Genet Metab 2008;93:275-81. https://doi.org/10.1016/j.ymgme.2007.09.006
Anderson G, Smith VV, Malone M, et al. Blood film examination for vacuolated lymphocytes in the diagnosis of metabolic disorders; retrospective experience of more than 2500 cases from a single centre. J Clin Pathol 2005;58:1305-310. https://doi.org/10.1136/jcp.2005.027045
Pascarella A, Terracciano C, Farina O, et al. Vacuolated PAS-positive lymphocytes as a hallmark of Pompe disease and other myopathies related to impaired autophagy. J Cell Physiol 2018;233:5829-37. https://doi.org/10.1002/jcp.26365
Kishnani PS, Steiner RD, Bali D, Berger K, Byrne BJ, Case LE, et al. Pompe disease diagnosis and management guideline. Genet Med 2006;8:267-288. https://doi.org/10.1097/01.gim.0000218152.87434.f3
van der Ploeg AT, Reuser AJ. Pompe's disease. Lancet 2008; 372, No. 9646, 1342-53. https://doi.org/10.1016/S0140-6736(08)61555-X
Chien YH, Hwu WL, Lee NC. Pompe disease: Early diagnosis and early treatment make a difference. Pediatr Neonatol. 2013;54(4):219-27. https://doi.org/10.1016/j.pedneo.2013.03.009
van der Ploeg AT, Kruijshaar ME, Toscano A, Laforêt P, Angelini C, Lachmann RH, et al. European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience. Eur J Neurol. 2017;24(6):768-e31. https://doi.org/10.1111/ene.13285
Reuser AJJ, van der Ploeg AT, Chien YH, Llerena J, Abbott MA, Clemens PR, et al. GAA variants and phenotypes among 1,079 patients with Pompe disease: Data from the Pompe Registry. Hum Mutat. 2019;40(11):2146-64. https://doi.org/10.1002/humu.23878
Sun A. Lysosomal storage disease overview. Ann Transl Med. 2018;6(24):476.-476. https://doi.org/10.21037/atm.2018.11.39
Schoser B. Pompe disease: what are we missing? Ann Transl Med. 2019;7(13):292-292. https://doi.org/10.21037/atm.2019.05.29
Kuo WL, Hirschhorn R, Huie ML, Hirschhorn K. Localization and ordering of acid alpha-glucosidase (GAA) and thymidine kinase (TK1) by fluorescence in situ hybridization. Hum Genet. 1996;97(3):404-6. https://doi.org/10.1007/BF02185782
Raben N, Nichols RC, Boerkoel C, Plotz P. Genetic defects in patients with glycogenosis type II (acid maltase deficiency). Muscle Nerve. 1995;18(14 S):S70-4. https://doi.org/10.1002/mus.880181415
Martiniuk F, Bodkin M, Tzall S, Hirschhorn R. Isolation and Partial Characterization of the Structural Gene for Human Acid Alpha Glucosidase. DNA Cell Biol. 1991;10(4):283-92. https://doi.org/10.1089/dna.1991.10.283
Kroos M, Hoogeveen-Westerveld M, van der Ploeg A, Reuser AJJ. The genotype-phenotype correlation in Pompe disease. Am J Med Genet Part C Semin Med Genet. 2012;160 C(1):59-68. https://doi.org/10.1002/ajmg.c.31318
Kroos MA, Mullaart RA, Van Vliet L, Pomponio RJ, Amartino H, Kolodny EH, et al. p.[G576S; E689K]: Pathogenic combination or polymorphism in Pompe disease? Eur J Hum Genet. 2008;16(8):875-9. https://doi.org/10.1038/ejhg.2008.34
Montagnese F, Barca E, Musumeci O, Mondello S, Migliorato A, Ciranni A, et al. Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment. J Neurol. 2015;262(4):968-78. https://doi.org/10.1007/s00415-015-7664-0
Montalvo ALE, Bembi B, Donnarumma M, Filocamo M, Parenti G, Rossi M, et al. Mutation profile of the GAA gene in 40 Italian patients with late onset glycogen storage disease type II. Hum Mutat. 2006;27(10):999-1006. https://doi.org/10.1002/humu.20374
Kroos MA, Pomponio RJ, Hagemans ML, Keulemans JLM, Phipps M, DeRiso M, et al. Broad spectrum of Pompe disease in patients with the same c.-32-13T?G haplotype. Neurology. 2007;68(2):110-5. https://doi.org/10.1212/01.wnl.0000252798.25690.76
Burton BK, Kronn DF, Hwu WL, Kishnani PS. The initial evaluation of patients after positive newborn screening: Recommended algorithms leading to a confirmed diagnosis of pompe disease. Pediatrics. 2017;140(July). https://doi.org/10.1542/peds.2016-0280D
Niño MY, in 't Groen SLM, Bergsma AJ, van der Beek NAME, Kroos M, Hoogeveen-Westerveld M, et al. Extension of the Pompe mutation database by linking disease-associated variants to clinical severity. Hum Mutat. 2019;40(11):1954-67. https://doi.org/10.1002/humu.23854
de Faria DOS, in 't Groen SLM, Hoogeveen-Westerveld M, Niño MY, van der Ploeg AT, Bergsma AJ, et al. Update of the Pompe variant database for the prediction of clinical phenotypes: Novel disease-associated variants, common sequence variants, and results from newborn screening. Hum Mutat. 2021;42(2):119-34. https://doi.org/10.1002/humu.24148
Zampieri S, Buratti E, Dominissini S, Montalvo AL, Pittis MG, Bembi B, et al. Splicing mutations in glycogen-storage disease type II: Evaluation of the full spectrum of mutations and their relation to patients phenotypes. Eur J Hum Genet. 2011;19(4):422-31. https://doi.org/10.1038/ejhg.2010.188
Raben N, Plotz P, Byrne B. Acid a-Glucosidase Deficiency (Glycogenosis Type II, Pompe Disease). Curr Mol Med. 2005;2(2):145-66. https://doi.org/10.2174/1566524024605789
Tarnopolsky M, Katzberg H, Petrof BJ, Sirrs S, Sarnat HB, Myers K, et al. Pompe Disease: Diagnosis and Management. Evidence-Based Guidelines from a Canadian Expert Panel. Can J Neurol Sci. 2016;43(4):472-85. https://doi.org/10.1017/cjn.2016.37
Tsai ACH, Hung YW, Harding C, Koeller DM, Wang J, Wong LJC. Next generation deep sequencing corrects diagnostic pitfalls of traditional molecular approach in a patient with prenatal onset of Pompe disease. Am J Med Genet Part A. 2017;173(9):2500-4. https://doi.org/10.1002/ajmg.a.38333
Musumeci O, Thieme A, Claeys KG, Wenninger S, Kley RA, Kuhn M, et al. Homozygosity for the common GAA gene splice site mutation c.-32-13T>G in Pompe disease is associated with the classical adult phenotypical spectrum. Neuromuscul Disord. 2015 Sep 1;25(9):719-24. https://doi.org/10.1016/j.nmd.2015.07.002
Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 2002 Jun 15;30(12):e57-e57. https://doi.org/10.1093/nar/gnf056
in 't Groen SLM, de Faria DOS, Iuliano A, van den Hout JMP, Douben H, Dijkhuizen T, et al. Novel GAA Variants and Mosaicism in Pompe Disease Identified by Extended Analyses of Patients with an Incomplete DNA Diagnosis. Mol Ther - Methods Clin Dev. 2020;17(June):337-48. https://doi.org/10.1016/j.omtm.2019.12.016
Wan L, Lee CC, Hsu CM, Hwu WL, Yang CC, Tsai CH, et al. Identification of eight novel mutations of the acid ?-glucosidase gene causing the infantile or juvenile form of glycogen storage disease type II. J Neurol. 2008;255(6):831-8. https://doi.org/10.1007/s00415-008-0714-0
Herzog A, Hartung R, Reuser AJJ, Hermanns P, Runz H, Karabul N, et al. A cross-sectional single-centre study on the spectrum of Pompe disease, German patients: Molecular analysis of the GAA gene, manifestation and genotype-phenotype correlations. Orphanet J Rare Dis. 2012;7(1). https://doi.org/10.1186/1750-1172-7-35
Becker JA, Vlach J, Raben N, Nagaraju K, Adams EM, Hermans MM, et al. The African origin of the common mutation in African American patients with glycogen-storage disease type II [3]. Am J Hum Genet. 1998;62(4):991-4. https://doi.org/10.1086/301788
Adams EM, Becker JA, Griffith L, Segal A, Plotz PH, Raben N. Glycogenosis type II: A juvenile-specific mutation with an unusual splicing pattern and a shared mutation in African Americans. Hum Mutat. 1997;10(2):128-34. https://doi.org/10.1002/(SICI)1098-1004(1997)10:2<128::AID-HUMU5>3.0.CO;2-G
Shieh JJ, Lin CY. Frequent mutation in Chinese patients with infantile type of GSD II in Taiwan: Evidence for a founder effect. Hum Mutat. 1998;11(4):306-12. https://doi.org/10.1002/(SICI)1098-1004(1998)11:4<306::AID-HUMU8>3.0.CO;2-S
Lin CY, Shieh JJ. Molecular study on the infantile form of Pompe disease in Chinese in Taiwan. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. 1996;37(2):115-121. PMID: 8935410
Hule ML, Chen AS, Tsujino S, Shanske S, Dimauro S, Engel AG, et al. Aberrant splicing in adult onset glycogen storage disease type II (GSDII): Molecular identification of an IVS1 (- 13T?G) mutation in a majority of patients and a novel IVS10 (+ 1GT ? CT) mutation. Hum Mol Genet. 1994;3(12):2231-6. https://doi.org/10.1093/hmg/3.12.2231
Boerkoel CF, Exelbert R, Nicastri C, Nichols RC, Miller FW, Plotz PH, et al. Leaky splicing mutation in the acid maltase gene is associated with delayed onset of glycogenosis type II. Am J Hum Genet. 1995;56(4):887-97. PMID: 7717400
Raben N, Nichols RC, Martiniuk F, Plotz PH. A model of mRNA splicing in adult lysosomal storage disease (glycogenosis type II). Hum Mol Genet. 1996;5(7):995-1000. https://doi.org/10.1093/hmg/5.7.995
Dardis A, Zanin I, Zampieri S, Stuani C, Pianta A, Romanello M, et al. Functional characterization of the common c.-32-13T>G mutation of GAA gene: Identification of potential therapeutic agents. Nucleic Acids Res. 2014;42(2):1291-302. https://doi.org/10.1093/nar/gkt987
Bergsma AJ, in 't Groen SLM, van den Dorpel JJA, van den Hout HJMP, van der Beek NAME, Schoser B, et al. A genetic modifier of symptom onset in Pompe disease. EBioMedicine [Internet]. 2019;43:553-61. https://doi.org/10.1016/j.ebiom.2019.03.048
Niño MY, Mateus HE, Fonseca DJ, Kroos MA, Ospina SY, Mejía JF, et al. Identification and Functional Characterization of GAA Mutations in Colombian Patients Affected by Pompe Disease. In: Brown G, Morava E, Peters V, Gibson KM, Zschocke J, editors. JIMD Reports - Case and Research Reports, 2012/4. Berlin, Heidelberg: Springer Berlin Heidelberg; 2013. p. 39-48. https://doi.org/10.1007/8904_2012_138
Puentes-Tellez MA, Lerma-Barbosa PA, Garzón-Jaramillo RG, Suarez DA, Espejo-Mojica AJ, Guevara JM, et al. A perspective on research, diagnosis, and management of lysosomal storage disorders in Colombia. Heliyon. 2020;6(3). https://doi.org/10.1016/j.heliyon.2020.e03635
Huie ML, Chen AS, Brooks SS, Grix A, Hirschhorn R. A de novo 13 nt deletion, a newly identified C647W missense mutation and a deletion of exon 18 in infantile onset glycogen storage disease type II (GSDII). Hum Mol Genet. 1994 Jul;3(7):1081-1087. https://doi.org/10.1093/hmg/3.7.1081
Kumamoto S, Katafuchi T, Nakamura K, Endo F, Oda E, Okuyama T, et al. High frequency of acid ?-glucosidase pseudodeficiency complicates newborn screening for glycogen storage disease type II in the Japanese population. Mol Genet Metab. 2009;97(3):190-5. https://doi.org/10.1016/j.ymgme.2009.03.004
Tajima Y, Matsuzawa F, Aikawa SI, Okumiya T, Yoshimizu M, Tsukimura T, et al. Structural and biochemical studies on Pompe disease and a "pseudodeficiency of acid ?-glucosidase." J Hum Genet. 2007;52(11):898-906. https://doi.org/10.1007/s10038-007-0191-9
Bali DS, Goldstein JL, Banugaria S, Dai J, Mackey J, Rehder C, et al. Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: Lessons learned from 10 years of clinical laboratory testing experience. Am J Med Genet Part C Semin Med Genet. 2012;160 C(1):40-9. https://doi.org/10.1002/ajmg.c.31319
Taglia A, Picillo E, D'Ambrosio P, Cecio MR, Viggiano E PL. Genetic counseling in Pompe disease. Acta Myol. 2011;30(3):179-181. PMID: 22616199
Llerena Junior JC, Nascimento OJM, Oliveira ASB, et al. Guidelines for the diagnosis, treatment and clinical monitoring of patients with juvenile and adult pompe disease. Arq Neuropsiquiatr. 2016;74(2):166-176. https://doi.org/10.1590/0004-282X20150194
Giraldo BO, Cornejo Ochoa JW, Arango D. Enfermedad de pompe: descripción de las características clínicas y de laboratorio de una familia colombiana. Acta Neurológica Colomb. 2011;27(4):231-236.
Al Jasmi F, Al Jumah M, Alqarni F, et al. Diagnosis and treatment of late-onset Pompe disease in the Middle East and North Africa region: Consensus recommendations from an expert group. BMC Neurol. 2015;15(1):1-17. https://doi.org/10.1186/s12883-015-0412-3
Leslie N BL. Pompe Disease. 2007 agosto 31 [actualizado 2017 mayo 11]. En: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mirzaa G, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle.
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.